Slough Estates PLC
20th April 2005
Slough Estates secures letting at Point Grand, South San Francisco
Slough Estates Plc, a leading provider of flexible business space, today
announces that Rinat Neuroscience has signed a lease with Slough Estates USA for
106,000 sq.ft of office and laboratory space on the Point Grand estate, South
San Francisco and will take occupancy of the facility in June 2005.
Rinat was formed in 2001 when Genentech, a leader in the development of
therapeutic proteins, narrowed its focus and spun out its key neuroscience
assets under a broad license to Rinat. Genentech invested significant R&D
resources in support of these assets over 15 years and Rinat is now building on
them to pioneer the development and commercialisation of proteins for the
treatment of diseases and disorders of the nervous system.
Ian Coull, Chief Executive of Slough Estates said: 'We are delighted to welcome
Rinat to Point Grand. The facility they have leased from us forms part of the
222,000 sq. ft campus vacated by Pfizer. Phase III of the campus has been let to
Exelixis and we have received enquiries for the remaining 50,000 sq. ft. of
space.'
Slough Estates is a leading provider of flexible business space in business
parks in Western Europe and North America, with over 1500 customers occupying
2,996,967 square metres of business space, with a total value of £3.9 billion.
Slough Estates' properties are in suburban locations in close proximity to the
main business centres, where there is long term demand for business
accommodation to serve these key economic regions. The company's main activities
are currently based around London, Brussels, Paris, Düsseldorf, San Francisco
and San Diego and the company continues to develop new business parks with the
long term objective of building shareholder value and enhancing its reputation
for quality buildings offering excellent value to customers.
www.sloughestates.com
For further information contact:
Shared Value Limited
Andrew Best / Emily Bruning
Tel: 020 7321 5022 / 5027
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.